The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2

Blog Article

Metastatic ZINC PICOLINATE gastric carcinoma is a mortal disease with a median survival of barely 10 months.An approximate 20% of the cases overexpress HER2, and among them, the combination of chemotherapy with trastuzumab is actually the first-line palliative treatment.However, after progression, sequential strategies of chemotherapy while maintaining trastuzumab have been barely researched.

We report the case of a Watch patient with a diagnosis of adenocarcinoma in the gastroesophageal junction with overexpression of HER2, in stage IV, treated with sequential chemotherapy and trastuzumab, who survived more than 5 years during the metastatic phase maintaining a good quality of life.